Результаты поиска

Самые горячие темы трансплантации стволовых клеток: резюме 8th Международный курс трансплантации и клеточной терапии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91:499–502. doi: 10.1002/ajh.24335. 6. …

Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Effects of short-term pretreatment with atorvastatin on mobilization of hematopoietic progenitor cells: A double-blind, randomized, controlled trial.

BackgroundDespite recent advances in mobilization techniques, a considerable portion of patients fail to mobilize sufficient number of cells for successful autologous stem cell transplantation. There are several studies available that have demonstrated enhanced mobilization of endothelial progenitor cells with atorvastatin. Therefore, this prospective trial was conducted to evaluate the mobilizing effect of atorvastatin on hematopoietic progenitor cells.Subjects and methodsForty-four autologous HSCT candidates were randomized in a double-blind controlled trial to receive atorvastatin 40 mg dai

Роль микробиомы в множестве миелом: новые знания и терапевтические возможности.

Множественная миелома — гематологический рак, описываемый распространением плазменных клеток в костном мозге, что вызывает иммунную дисфункцию и другие аномалии. Микробиом кишечника, микробное сообщество в желудочно-кишечном тракте, было обнаружено, что он модифицирует системный иммунитет, воспаление и метаболизм. Хотя взаимосвязь между кишечным микробиомом и множеством миелома была обнаружена в недавних исследованиях, существует пробел в знаниях, связывающий воздействие микробиома на патогенез и лечение множественной миеломы. Несбалансированность в кишечном микробиоме, дисбиозе, может влиять

Исключительные долгосрочные ответные меры, принятые в ходе испытаний ОКЕАН и ГОРИЗОН: мелфлюфен-дексаметасон в качестве расширения возможностей лечения повторной/нереакторной множественной миеломы в эпоху новой иммунотерапии?

Алкилатные агенты представляют собой первый эффективный класс наркотиков в множестве миеломы (ММ), но после внедрения новых эффективных лекарственных средств их потребление постепенно сокращается и в настоящее время переводится на автологическую трансплантацию стволовых клеток (ASCT) и несколько других объектов. Тем не менее, США одобрили комбинацию мелфлюфена (пиптидно-наркотика, про-наркотика мелфалана) и дексаметасона. Управление по контролю за продуктами питания и лекарственными препаратами (УПП) для пациентов с трехклассными отклонениями после ≥ 4 :: предыдущая терапия (ЛОТ) по результата

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy.

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed and refractory myeloma, with excellent outcomes and a tolerable safety profile. High dose chemotherapy with autologous hematopoietic stem cell transplantation (AHCT) is established as a mainstream of newly diagnosed multiple myeloma (NDMM) management in patients who are young and fit enough to tolerate such intensity. This standard was developed based on randomized trials comparing AHCT to chemotherapy in the era prior to novel agents. More recently, larger studies have primarily shown a progression fr

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.

Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time. Given that MM is the second most common blood cancer with a characteristic and unavoidable relapse/refractory state during the course of the disease, the development of new therapeutic modalities is crucial. Belantamab mafodotin (belamaf, GSK2857916) is a first-in-class therapeutic, indicated for patients who have

The evolving role and utility of off-label drug use in multiple myeloma.

The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 19 drug approvals and at least eight different active classes. The advances seen in MM therapy have relied on both a structured approach to obtaining new labels and cautious off-label drug use. Although there are country and regional differences in drug approval processes, many of the basic principles behind off-label drug use in MM can be summarized into four main categories: 1) use of a therapy pri

What Is New in the Treatment of Smoldering Multiple Myeloma?

Smoldering multiple myeloma (SMM), an asymptomatic plasma cell neoplasm, is currently diagnosed according to the updated IMWG criteria, which reflect an intermediate tumor mass between monoclonal gammopathy of undetermined significance (MGUS) and active MM. However, SMM is a heterogeneous entity and individual case may go from an "MGUS-like" behavior to "early MM" with rapid transformation into symptomatic disease. This wide range of clinical outcomes poses challenges for prognostication and management of individual patients. However, initial studies showed a benefit in terms of progression or

Совпадение в полном тексте источника
… Such approaches generally include triplets with a proteasome inhibitor (PI), an immunomodulatory drug (IMID) and dexamethasone. In some instances, treatments include monoclonal antibodies or even autologous stem cell transplantation (AuSCT). … The all-oral triplet ixazomib-lenalidomide-dexamethasone (IxRd) is being tested in a phase 2 trial for patients with high-risk SMM [ 75 ], where a nine-cycle induction schedule is followed by 15 cycle of maintenance with ixazomib and lenalidomide. …

Daratumumab у поддающихся трансплантации пациентов с недавно диагностированным множественным миэломой: окончательный анализ клинических подгрупп в ГРИФФИН.

Случайный, фазы 2 Исследование ГРИФФИНNCT02874742) оценивалась " даратумумаб " плюс " линалидомид " / " бортезомиб "/дексаметасон " (D-RVD) в недавно диагностированной миеломе (NDMM). Мы представляем окончательный послекризисный анализ (средняя последующая деятельность, 49.6 - месяцев) подгрупп, имеющих отношение к клиническим заболеваниям, включая пациентов с повышенным риском цитогенетических аномалий (СПЧ) в соответствии с пересмотренным определением (del[17p], t[4;14], t[14;16], t[14;20], и/или прирост/и/или[1q21]). Полученные пациенты 4 индукционные цикл

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric antigen receptor (CAR) T-cell therapies have improved outcomes of patients with hematologic malignancies. B-cell maturation antigen (BCMA) is the current target antigen of choice for most CAR T-cell products under investigation for MM. However, their shortcomings deal with logistical and clinical challenges, including limited availability, manufacturing times, and toxicities. This article provides an overview of rec

Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective.

Multiple myeloma (MM) is a prevalent hematological malignancy. Resource-constrained settings such as the Middle East are particularly burdened by the increasing trends in MM morbidity and mortality in addition to challenges in the management of MM. It thus becomes necessary to identify and address debatable areas of current practice and gaps in the management of MM in the Middle East. With a special focus on the Lebanese situation, the first-line treatment of the very elderly (> 80 years old) is discussed, in addition to the impact of relapse type (biochemical or clinical relapse) on maintenan

A Focus on Newly Diagnosed Multiple Myeloma.

Multiple myeloma (MM) is an incurable plasma cell disorder that affects nearly 35,000 people annually. Over 149,000 individuals are estimated to live in the United States with MM. Research has generated a greater understanding of the pathology of this disease, now combined with mature clinical trial data that support the use of combination therapy in treatment. This article focuses on updated diagnosis, prognosis, and treatment of newly diagnosed patients. While the diagnosis of MM remains based on the 2014 International Myeloma Working Group (IMWG) guidelines, we review these and updated reco

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients.

OBJECTIVE: To explore the efficacy and safety of intermittent, oral famciclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. METHOD: We retrospectively analyzed the incidence of bortezomib treatment-related varicella-zoster virus reactivation in 719 newly-diagnosed multiple myeloma patients receiving intermittent oral famciclovir prophylaxis, continuous oral acyclovir prophylaxis or no prophylaxis. The definition of intermittent oral famciclovir prophylaxis was oral famciclovir at a dose of 250mg twice daily for 9 days after finishing the last dose of bortezo

Keyword Index for Volume 106

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Functional Recovery Following Intensive Upfront Therapy in Multiple Myeloma Patients With Poor Performance Status: A Case Series.

Patients with newly diagnosed multiple myeloma (MM) may present with profound functional impairment due to high disease burden, and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 4 is often viewed as a barrier to intensive therapy despite potential reversibility. We report six newly diagnosed, bedbound MM patients (ECOG 4) treated with individualized multi-agent regimens incorporating proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies when feasible. Advanced features included extensive skeletal disease, renal dysfunction, hyperviscosity

Haematopoietic Stem Cell Transplant Trends in Pakistan: Activity Survey from Pakistan Bone Marrow Transplant Group.

Pakistan is the fifth most populous country with a population of 225 million and has health expenditure accounting for only 2.8 percent of gross domestic product (GDP). Accordingly, there are a limited number of haematology-oncology and transplant centers in the country. The Pakistan Blood and Marrow Transplant (PBMT) group was established in 2020, and this report is the first activity survey from January 2021 to December 2022 focusing on the trends of matched-related donor, haploidentical, and autologous transplants in a developing country. A total of 12 transplant centers contributed data on

Keyword Index for Volume 98

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… 1059 transforming growth factor- β 1 356 transitional cell carcinoma 86 transitions in care 529 translation 1696 trastuzumab 1525 treatment 888, 1944 treatment decisions 1769 treatment delay 1197 treatment induced bone loss 1736 T reg 1258 trial 54 trial results 34 triple negative 277 triplets …

Abstract Book for the 3rd European Myeloma Network Meeting

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.